Analysts have been eager to weigh in on the Healthcare sector with new ratings on CareDx (CDNA – Research Report), Amgen (AMGN – Research Report) and Orasure Technologies (OSUR – Research Report).
CareDx (CDNA)
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on CareDx, with a price target of $22.00. The company’s shares closed last Thursday at $14.78, close to its 52-week high of $16.15.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CareDx with a $18.00 average price target, implying a 22.2% upside from current levels. In a report issued on May 10, Goldman Sachs also maintained a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Amgen (AMGN)
Jefferies analyst Michael Yee maintained a Buy rating on Amgen today and set a price target of $375.00. The company’s shares closed last Thursday at $314.72, close to its 52-week high of $329.72.
According to TipRanks.com, Yee is a 2-star analyst with an average return of
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $322.75, representing a 2.6% upside. In a report issued on May 3, William Blair also upgraded the stock to Buy.
Orasure Technologies (OSUR)
J.P. Morgan analyst Casey Woodring maintained a Hold rating on Orasure Technologies on May 12 and set a price target of $6.00. The company’s shares closed last Thursday at $5.23.
According to TipRanks.com, Woodring is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Orasure Technologies with a $6.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CDNA:
- CareDx downgraded to Market Perform from Outperform at Raymond James
- CareDx reports Q1 EPS (3c), consensus (21c)
- HHS kidney transplant initiative ‘very bullish’ for CareDx, says Craig-Hallum
- HHS announces Increasing Organ Transplant Access model
- Craig-Hallum upgrades CareDx to Buy, raises price target to $15
